In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

BeiGene nets $875.5mm via Hong Kong IPO

Executive Summary

BeiGene Ltd. (immuno-oncology) netted $875.5mm through its initial public offering on the Main Board of the Stock Exchange of Hong Kong Ltd. (SEHK). The company sold 65.6mm ordinary shares at $13.76 (the mid-point of its $12.03-14.22 range). Of the total, 5.9mm shares were offered to the public in Hong Kong and 59.7mm shares were offered globally. BeiGene completed its US initial public offering on the Nasdaq Global Select Market in February 2016, through which it netted $170mm with the sale of 7.6mm American Depositary Shares (representing 98.7mm ordinary). Current proceeds will go towards development, regulatory activities, and future commercialization of zanubrutinib (mantle cell lymphoma), tislelizumab (classical Hodgkin's lymphoma), and pamiparib (solid tumors including ovarian, gastric, and brain tumors), and will also support pipeline expansion in cancer and possibly other indications.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register